JP2020515611A - 疼痛の処置のための１１，１３−修飾サキシトキシン - Google Patents

疼痛の処置のための１１，１３−修飾サキシトキシン Download PDF

Info

Publication number
JP2020515611A
JP2020515611A JP2019553573A JP2019553573A JP2020515611A JP 2020515611 A JP2020515611 A JP 2020515611A JP 2019553573 A JP2019553573 A JP 2019553573A JP 2019553573 A JP2019553573 A JP 2019553573A JP 2020515611 A JP2020515611 A JP 2020515611A
Authority
JP
Japan
Prior art keywords
alkyl
halo
optionally substituted
aryl
alkoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019553573A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020515611A5 (enExample
Inventor
ジョン マルケイヒー，
ジョン マルケイヒー，
ハッサン パジョヘシュ，
ハッサン パジョヘシュ，
ジョージ ミルジャニッチ，
ジョージ ミルジャニッチ，
アントン デルウィグ，
アントン デルウィグ，
ジェイコブ ベックリー，
ジェイコブ ベックリー，
グラント マサアキ シブヤ，
グラント マサアキ シブヤ，
ボイス， ジャスティン デュ
ボイス， ジャスティン デュ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Leland Stanford Junior University
Original Assignee
Leland Stanford Junior University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leland Stanford Junior University filed Critical Leland Stanford Junior University
Publication of JP2020515611A publication Critical patent/JP2020515611A/ja
Publication of JP2020515611A5 publication Critical patent/JP2020515611A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Rheumatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2019553573A 2017-03-29 2018-03-29 疼痛の処置のための１１，１３−修飾サキシトキシン Pending JP2020515611A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762478519P 2017-03-29 2017-03-29
US62/478,519 2017-03-29
PCT/US2018/025304 WO2018183782A1 (en) 2017-03-29 2018-03-29 11,13-modified saxitoxins for the treatment of pain

Publications (2)

Publication Number Publication Date
JP2020515611A true JP2020515611A (ja) 2020-05-28
JP2020515611A5 JP2020515611A5 (enExample) 2021-05-06

Family

ID=62002497

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019553573A Pending JP2020515611A (ja) 2017-03-29 2018-03-29 疼痛の処置のための１１，１３−修飾サキシトキシン

Country Status (5)

Country Link
US (1) US11279706B2 (enExample)
EP (1) EP3601290B1 (enExample)
JP (1) JP2020515611A (enExample)
CN (1) CN110914276A (enExample)
WO (1) WO2018183782A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020515610A (ja) * 2017-03-29 2020-05-28 サイトワン セラピューティクス， インコーポレイテッド 疼痛の処置のための１１，１３−修飾サキシトキシン：

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018183782A1 (en) 2017-03-29 2018-10-04 Siteone Therapeutics, Inc. 11,13-modified saxitoxins for the treatment of pain
WO2020072835A1 (en) * 2018-10-03 2020-04-09 Siteone Therapeutics, Inc. 11,13-modified saxitoxins for the treatment of pain
MX2022006865A (es) 2019-12-06 2022-07-11 Vertex Pharma Tetrahidrofuranos sustituidos como moduladores de canales de sodio.
US20230339958A1 (en) * 2020-08-14 2023-10-26 Siteone Therapeutics, Inc. Non-hydrated ketone inhibitors of nav1.7 for the treatment of pain
BR112023025264A2 (pt) 2021-06-04 2024-02-20 Vertex Pharma Formas farmacêuticas sólidas e regimes posológicos compreendendo (2r,3s,4s,5r)-4-[[3- (3,4-difluoro-2-metóxi-fenil)-4,5-dimetil-5-(trifluorometil) tetra-hidrofuran-2-carbonil]amino ]piridina-2-carboxamida
WO2022256842A1 (en) 2021-06-04 2022-12-08 Vertex Pharmaceuticals Incorporated Hydroxy and (halo)alkoxy substituted tetrahydrofurans as modulators of sodium channels
DK4347031T3 (da) 2021-06-04 2025-12-01 Vertex Pharma N-(hydroxyalkyl-(hetero)aryl)-tetrahydrofuran-carboxamider som modulatorer af natriumkanaler
WO2022256676A1 (en) 2021-06-04 2022-12-08 Vertex Pharmaceuticals Incorporated Substituted tetrahydrofuran analogs as modulators of sodium channels
JP2024520648A (ja) 2021-06-04 2024-05-24 バーテックス ファーマシューティカルズ インコーポレイテッド ナトリウムチャネルの調節因子としての置換テトラヒドロフラン－２－カルボキサミド
US20240400544A1 (en) 2021-06-04 2024-12-05 Vertex Pharmaceuticals Incorporated N-(hydroxyalkyl (hetero)aryl) tetrahydrofuran carboxamide analogs as modulators of sodium channels
EP4511117A1 (en) 2022-04-22 2025-02-26 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain
CA3256604A1 (en) 2022-04-22 2023-10-26 Vertex Pharmaceuticals Incorporated HETEROARYL COMPOUNDS FOR PAIN RELIEF
JP2025513454A (ja) 2022-04-22 2025-04-24 バーテックス ファーマシューティカルズ インコーポレイテッド 疼痛の治療のためのヘテロアリール化合物
GEAP202516632A (en) 2022-04-22 2025-02-25 Vertex Pharma Heteroaryl compounds for the treatment of pain
CN120603815A (zh) 2022-12-06 2025-09-05 沃泰克斯药物股份有限公司 钠通道的取代四氢呋喃调节剂的合成方法
WO2025090465A1 (en) 2023-10-23 2025-05-01 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain
WO2025090480A1 (en) 2023-10-23 2025-05-01 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain
WO2025090516A1 (en) 2023-10-23 2025-05-01 Vertex Pharmaceuticals Incorporated Methods of preparing compounds for treating pain and solid forms thereof
TW202535867A (zh) 2023-10-23 2025-09-16 美商維泰克斯製藥公司 用於治療疼痛之鈉通道調節劑及其固體形式的製備方法
US20250186419A1 (en) 2023-12-07 2025-06-12 Vertex Pharmaceuticals Incorporated Dosing regimens for treating pain

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012526147A (ja) * 2009-05-07 2012-10-25 ザ ボード オブ トラスティーズ オブ ザ リーランド スタンフォード ジュニア ユニバーシティ 疼痛の研究、画像化および治療方法、ならびに疼痛の研究、画像化および治療のための組成物
JP2013519653A (ja) * 2010-02-10 2013-05-30 ファイトトックス リミテッド サキシトキシン誘導体での触覚の喪失の処置
JP2020515610A (ja) * 2017-03-29 2020-05-28 サイトワン セラピューティクス， インコーポレイテッド 疼痛の処置のための１１，１３−修飾サキシトキシン：

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3957996A (en) 1971-12-08 1976-05-18 Astra Pharmaceutical Products, Inc. Pharmaceutical local anesthetic compositions
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
KR890002631B1 (ko) 1984-10-04 1989-07-21 몬산토 캄파니 생물학적으로 활성인 소마토트로핀을 지속적으로 유리하는 조성물
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
PH30995A (en) 1989-07-07 1997-12-23 Novartis Inc Sustained release formulations of water soluble peptides.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
TW333456B (en) 1992-12-07 1998-06-11 Takeda Pharm Ind Co Ltd A pharmaceutical composition of sustained-release preparation the invention relates to a pharmaceutical composition of sustained-release preparation which comprises a physiologically active peptide.
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
US6087324A (en) 1993-06-24 2000-07-11 Takeda Chemical Industries, Ltd. Sustained-release preparation
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
WO1997001331A2 (en) 1995-06-27 1997-01-16 Takeda Chemical Industries, Ltd. Method of producing sustained-release preparation
TW448055B (en) 1995-09-04 2001-08-01 Takeda Chemical Industries Ltd Method of production of sustained-release preparation
JP2909418B2 (ja) 1995-09-18 1999-06-23 株式会社資生堂 薬物の遅延放出型マイクロスフイア
US5980945A (en) 1996-01-16 1999-11-09 Societe De Conseils De Recherches Et D'applications Scientifique S.A. Sustained release drug formulations
US6264970B1 (en) 1996-06-26 2001-07-24 Takeda Chemical Industries, Ltd. Sustained-release preparation
US6419961B1 (en) 1996-08-29 2002-07-16 Takeda Chemical Industries, Ltd. Sustained release microcapsules of a bioactive substance and a biodegradable polymer
CA2217134A1 (en) 1996-10-09 1998-04-09 Sumitomo Pharmaceuticals Co., Ltd. Sustained release formulation
ES2221019T3 (es) 1996-10-31 2004-12-16 Takeda Chemical Industries, Ltd. Preparacion de liberacion mantenida.
DE69719367T2 (de) 1996-12-20 2003-10-16 Takeda Chemical Industries, Ltd. Verfahren zur herstellung einer zusammensetzung mit verzoegerter abgabe
EP0857972A1 (en) 1997-01-24 1998-08-12 Tepual, S.A. Immunoassay for the detection and quantitation of toxins causing paralytic shellfish poisoning
US5891474A (en) 1997-01-29 1999-04-06 Poli Industria Chimica, S.P.A. Time-specific controlled release dosage formulations and method of preparing same
CN1081034C (zh) 1997-03-07 2002-03-20 潘心富 一种双胍基氢化嘌呤环类化合物的戒毒药
US6030974A (en) 1997-04-02 2000-02-29 The Regents Of The University Of California Method of anesthesia
AU7389098A (en) 1997-05-16 1998-12-08 Brigham And Women's Hospital Local anesthetic formulations
US6613358B2 (en) 1998-03-18 2003-09-02 Theodore W. Randolph Sustained-release composition including amorphous polymer
KR19990085365A (ko) 1998-05-16 1999-12-06 허영섭 지속적으로 약물 조절방출이 가능한 생분해성 고분자 미립구 및그 제조방법
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
CN1382443A (zh) 2001-04-25 2002-12-04 威克斯医疗仪器有限公司 钠离子通道阻断剂在制备用于局部神经麻醉或镇痛的药物中的应用
JP2003012699A (ja) 2001-07-04 2003-01-15 Japan Science & Technology Corp 抗麻酔性貝毒抗体の製法、新規抗体、該抗体を用いるｅｌｉｓａ測定キット、該製法による系標識毒標品
CN1194693C (zh) 2002-01-11 2005-03-30 中国科学院海洋研究所 麻痹性贝毒毒素作为制备疗治疼痛病症药物的应用
US20050202093A1 (en) 2002-12-02 2005-09-15 Kohane Daniel S. Prolonged suppression of electrical activity in excitable tissues
AU2003901897A0 (en) 2003-02-12 2003-05-08 Australian Institute Of Marine Science Conjugate
US20050137177A1 (en) 2003-12-18 2005-06-23 Shafer Steven L. Ester combination local anesthetic
WO2005110418A2 (en) 2004-05-07 2005-11-24 Phytotox Limited Transdermal administration of phycotoxins
CA2607589A1 (en) 2004-05-07 2005-11-24 Phytotox Limited Methods of treating wounds with gonyautoxins
WO2006032459A1 (en) * 2004-09-22 2006-03-30 Laboratorios Del Dr. Esteve S.A. Tetrodotoxin and its derivatives for the treatment of peripheral-nervously derived neuropathic pain
RU2277097C1 (ru) 2004-12-27 2006-05-27 Институт Молекулярной Генетики Российской Академии Наук (Имг Ран) Высокомеченный тритием дигидрохлорид [3h]сакситоксина
CN101513408A (zh) 2008-02-19 2009-08-26 熊平 双胍基嘌呤环类衍生物制备提高抗癌药药效的新应用
AU2009281732A1 (en) 2008-08-15 2010-02-18 Georgetown University Na channels, disease, and related assays and compositions
EP3009427B1 (en) 2011-03-03 2019-12-18 Zalicus Pharmaceuticals Ltd. Benzimidazole inhibitors of the sodium channel
CA2944549A1 (en) 2014-04-09 2015-10-15 Siteone Therapeutics, Inc. 10',11'-modified saxitoxin useful for the treatment of pain
US10112953B2 (en) 2015-09-30 2018-10-30 Siteone Therapeutics, Inc. 11,13-modified saxitoxins for the treatment of pain
WO2018183782A1 (en) 2017-03-29 2018-10-04 Siteone Therapeutics, Inc. 11,13-modified saxitoxins for the treatment of pain
WO2020072835A1 (en) 2018-10-03 2020-04-09 Siteone Therapeutics, Inc. 11,13-modified saxitoxins for the treatment of pain

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012526147A (ja) * 2009-05-07 2012-10-25 ザ ボード オブ トラスティーズ オブ ザ リーランド スタンフォード ジュニア ユニバーシティ 疼痛の研究、画像化および治療方法、ならびに疼痛の研究、画像化および治療のための組成物
JP2013519653A (ja) * 2010-02-10 2013-05-30 ファイトトックス リミテッド サキシトキシン誘導体での触覚の喪失の処置
JP2020515610A (ja) * 2017-03-29 2020-05-28 サイトワン セラピューティクス， インコーポレイテッド 疼痛の処置のための１１，１３−修飾サキシトキシン：

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
MAO, HUA; FIEBER, LYNNE A.; GAWLEY, ROBERT E.: "Novel Modulator of NaV1.1 and NaV1.2 Na+ Channels in Rat Neuronal Cells", ACS MEDICINAL CHEMISTRY LETTERS, vol. 1(3),, JPN6022005241, 2010, pages 135 - 138, ISSN: 0004879189 *
THEODORA W. GREENE, PROTECTIVE GROUPS IN ORGANIC SYNTHESIS, vol. THIRD EDITION, JPN6022005244, 1999, US, pages 511 - 603, ISSN: 0004879190 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020515610A (ja) * 2017-03-29 2020-05-28 サイトワン セラピューティクス， インコーポレイテッド 疼痛の処置のための１１，１３−修飾サキシトキシン：
JP7090100B2 (ja) 2017-03-29 2022-06-23 サイトワン セラピューティクス， インコーポレイテッド 疼痛の処置のための１１，１３－修飾サキシトキシン：

Also Published As

Publication number Publication date
US20200102317A1 (en) 2020-04-02
EP3601290B1 (en) 2021-11-24
CN110914276A (zh) 2020-03-24
US11279706B2 (en) 2022-03-22
WO2018183782A1 (en) 2018-10-04
EP3601290A1 (en) 2020-02-05

Similar Documents

Publication Publication Date Title
US11279706B2 (en) 11,13-modified saxitoxins for the treatment of pain
US11834456B2 (en) 11,13-modified saxitoxins for the treatment of pain
US12162886B2 (en) 11,13-modified saxitoxins for the treatment of pain
EP4196482B1 (en) Non-hydrated ketone inhibitors of nav1.7 for the treatment of pain
US10112953B2 (en) 11,13-modified saxitoxins for the treatment of pain
CA2944549A1 (en) 10',11'-modified saxitoxin useful for the treatment of pain
RU2778455C2 (ru) 11,13-модифицированные сакситоксины для лечения боли
WO2025160286A1 (en) 2-aryl cycloalkyl and heterocycloalkyl inhibitors of nav1.8 for the treatment of pain

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210329

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210329

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220203

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220209

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220922